It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Heterotypic amyloid interactions between related protein sequences have been observed in functional and disease amyloids. While sequence homology seems to favour heterotypic amyloid interactions, we have no systematic understanding of the structural rules determining such interactions nor whether they inhibit or facilitate amyloid assembly. Using structure-based thermodynamic calculations and extensive experimental validation, we performed a comprehensive exploration of the defining role of sequence promiscuity in amyloid interactions. Using tau as a model system we demonstrate that proteins with local sequence homology to tau amyloid nucleating regions can modify fibril nucleation, morphology, assembly and spreading of aggregates in cultured cells. Depending on the type of mutation such interactions inhibit or promote aggregation in a manner that can be predicted from structure. We find that these heterotypic amyloid interactions can result in the subcellular mis-localisation of these proteins. Moreover, equilibrium studies indicate that the critical concentration of aggregation is altered by heterotypic interactions. Our findings suggest a structural mechanism by which the proteomic background can modulate the aggregation propensity of amyloidogenic proteins and we discuss how such sequence-specific proteostatic perturbations could contribute to the selective cellular susceptibility of amyloid disease progression.
In this work, Louros et al. uncover a rule book for interactions of amyloids with other proteins. This grammar was shown to promote cellular spreading of tau aggregates in cells, but can also be harvested to develop structure-based aggregation blockers.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Switch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium (GRID:grid.511015.1); KU Leuven, Switch Laboratory, Department of Cellular and Molecular Medicine, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
2 VIB Screening Core, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Ghent University, Centre for Bioassay Development and Screening (C-BIOS), Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)
3 KU Leuven, Leuven Brain Institute, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Laboratory for Neuropathology, KU Leuven, and Department of Pathology, UZ Leuven, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338)